It has been reported that PPARα activation upregulates its target genes (LPL, ACOX1, and CPT-1a) expression, enhancing lipid degradation and fatty acid oxidation, which ameliorates hepatic steatosis, dyslipidemia, and insulin resistance [29]. This evidence concerns the gene LPL and fatty liver disease.